Gwen Fyfe and Norman Selby join Infinity Pharmaceuticals

US-based drug discovery and development firm Infinity Pharmaceuticals has appointed Gwen Fyfe and Norman Selby to its board of directors.

Fyfe has over 20 years experience in drug development, including 12 years at Genentech, now part of Roche.

At Genentech she held several senior positions, including VP of its oncology development and VP of the Avastin franchise team. As well as Avastin, Fyfe worked on the development teams of several other major Roche drugs, including Rituxan, Herceptin and Tarceva.

Since she left Genentech in 2009, Fyfe has acted as a consultant for several venture capital firms and biotech companies.

Selby is currently senior adviser at private equity firm Perseus, as well as executive chair of healthcare information company Real Endpoints.

Prior to joining Perseus in 2005, Selby was president and CEO of TransForm Pharmaceuticals, a speciality pharma company focused on innovation in the form and formulation of drug compounds, which was later acquired by Johnson & Johnson.

His other previous roles include executive VP at Citigroup/Citicorp from 1997 to 2000 and several senior positions at McKinsey & Company, where he was a senior partner, including head of the firm's global pharmaceuticals and medical products practice.

Leaving Infinity's board of directors will be James Tananbaum and Arnold Levine, who are both retiring in May. They had been members of Infinity's board of directors since the founding of its predecessor company in 2001.